

Leroy A. Richardson,
*Chief, Information Collection Review Office,
 Office of Scientific Integrity, Office of the
 Associate Director for Science, Office of the
 Director, Centers for Disease Control and
 Prevention.*

[FR Doc. 2017-17699 Filed 8-21-17; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND
 HUMAN SERVICES**

**Administration for Children and
 Families**

**Submission for OMB Review;
 Comment Request**

Title: Application Requirements for
 the Low Income Home Energy
 Assistance Program (LIHEAP) Plan.

OMB No.: 0970-0075.

Description: States, including the
 District of Columbia, tribes, tribal
 organizations, and U.S. territories

applying for LIHEAP block grant funds
 must, prior to receiving federal funds,
 submit an annual application (Model
 Plan, ACF-122) that meets the LIHEAP
 statutory and regulatory requirements.
 In addition to the Model Plan, grantees
 are also required to complete the
 Mandatory Grant Application SF-424-
 Mandatory, which is the first section of
 the Model Plan.

The LIHEAP Model Plan is an
 electronic form and is submitted to the
 Administration for Children and
 Families (ACF), Office of Community
 Services (OCS) through the On-line Data
 Collection (OLDC) system within
 GrantSolutions, which is currently
 being used by all LIHEAP grantees to
 submit other required LIHEAP reporting
 forms. In order to reduce the reporting
 burden, all data entries from each
 grantee's prior year's submission of the
 Model Plan in OLDC is saved and re-
 populated (cloned) into the form for the
 following fiscal year's application.

OCS seeks renewal of this form
 without any changes. A sample model
 plan showing these proposed changes
 can be found on the U.S. Department of
 Health and Human Services, ACF/OCS
 LIHEAP Program Resources page at:
[https://www.acf.hhs.gov/ocs/resource/
 funding-applications](https://www.acf.hhs.gov/ocs/resource/funding-applications).

On April 3, 2017, ACF published a
Federal Register Notice seeking 60 days
 of public comment on this proposed
 information collection. One state
 grantee provided comments. ACF
 revised the Plan to address the
 comments by ensuring that open field
 boxes and attachment capability are
 available if the answer choices are
 insufficient to address the questions.

The revised model plan can be
 viewed on the OCS Web site at: [http://
 www.acf.hhs.gov/programs/ocs/
 programs/liheap](http://www.acf.hhs.gov/programs/ocs/programs/liheap).

Respondents: State, the District of
 Columbia, U.S. Territories and Tribal
 governments.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
LIHEAP Detailed Model Plan	210	1	0.50	105

*Estimated Total Annual Burden
 Hours (all respondents):* 105.

Additional Information: Copies of the
 proposed collection may be obtained by
 writing to the Administration for
 Children and Families, Office of
 Planning, Research and Evaluation, 330
 C Street SW., Washington, DC 20201.
 Attention Reports Clearance Officer. All
 requests should be identified by the title
 of the information collection. Email
 address: infocollection@acf.hhs.gov.

OMB Comment: OMB is required to
 make a decision concerning the
 collection of information between 30
 and 60 days after publication of this
 document in the **Federal Register**.
 Therefore, a comment is best assured of
 having its full effect if OMB receives it
 within 30 days of publication. Written
 comments and recommendations for the
 proposed information collection should
 be sent directly to the following: Office
 of Management and Budget, Paperwork
 Reduction Project, Email: [OIRA_
 SUBMISSION@OMB.EOP.GOV](mailto:OIRA_SUBMISSION@OMB.EOP.GOV), Attn:
 Desk Officer for the Administration for
 Children and Families.

Robert Sargis,
Reports Clearance Officer.

[FR Doc. 2017-17681 Filed 8-21-17; 8:45 am]

BILLING CODE 4184-01-P

**DEPARTMENT OF HEALTH AND
 HUMAN SERVICES**

Food and Drug Administration

[Docket No. FDA-2017-N-4885]

**Pediatric Advisory Committee; Notice
 of Meeting; Establishment of a Public
 Docket; Request for Comments**

AGENCY: Food and Drug Administration,
 HHS.

ACTION: Notice; establishment of a
 public docket; request for comments.

SUMMARY: The Food and Drug
 Administration (FDA or the Agency)
 announces a forthcoming public
 advisory committee meeting of the
 Pediatric Advisory Committee (PAC).
 The general function of the committee is
 to provide advice and recommendations
 to the Agency on FDA's regulatory
 issues. The meeting will be open to the
 public. FDA is establishing a docket for
 public comments.

DATES: The meeting will be held on
 September 11, 2017, from 8:30 a.m. to
 5:30 p.m. and September 12, 2017, from
 8:30 a.m. to 1 p.m.

ADDRESSES: Hilton Washington DC/
 Rockville Hotel & Executive Meeting
 Center, 1750 Rockville Pike, Rockville,
 MD 20852. The hotel's telephone

number is 301-468-1100. Answers to
 commonly asked questions including
 information regarding special
 accommodations due to a disability,
 visitor parking, and transportation may
 be accessed at [http://www3.hilton.com/
 en/hotels/maryland/hilton-washington-
 dc-rockville-hotel-and-executive-
 meeting-ctr-IADMRHF/index.html](http://www3.hilton.com/en/hotels/maryland/hilton-washington-dc-rockville-hotel-and-executive-meeting-ctr-IADMRHF/index.html).

FDA is establishing a docket for
 public comment on this document. The
 docket number is FDA-2017-N-4885.
 The docket will close on September 13,
 2017. Submit either electronic or
 written comments on this public
 meeting by that date. Late, untimely
 comments will not be considered.
 Electronic comments must be submitted
 on or before September 13, 2017. The
<https://www.regulations.gov> electronic
 filing system will accept comments
 until midnight Eastern Time at the end
 of September 13, 2017. Comments
 received by mail/hand delivery/courier
 (for written/paper submissions) will be
 considered timely if they are
 postmarked or the delivery service
 acceptance receipt is on or before that
 date.

Comments received on or before
 August 28, 2017, will be provided to the
 committee. Comments received after
 that date will be taken into
 consideration by FDA.